Outcome of the Board Meeting held on 30.05.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vanta Bioscience's board approved audited financial results for FY 2025-26 ending March 31, 2026. The company achieved a significant turnaround, reporting standalone net profit of Rs. 11.98 Lacs compared to a loss of Rs. 265.95 Lacs in the previous year. Total revenue grew to Rs. 197.59 Lacs from Rs. 116.66 Lacs. The board also re-appointed Mr. Dopesh Raja Mulakala as Managing Director for another 3-year term (April 18, 2026 to April 17, 2029), subject to shareholder approval. Statutory auditors Mathesh & Ramana issued an unmodified and unqualified opinion. The company's cash flow from operations was negative at Rs. -521.93 Lacs, while borrowings increased significantly to Rs. 3,120.76 Lacs in non-current liabilities.
The company has returned to profitability after two consecutive loss-making years, which is a positive signal for shareholders. However, the significant increase in debt levels and negative operating cash flow warrant monitoring. The MD re-appointment provides continuity in leadership.